Avalyn Pharma expands Boston sublease with CRISPR Therapeutics
Avalyn amended its sublease at 105 West First Street to nearly 13,708 square feet, adding about $924,000 in future lease payments.
Avalyn Pharma Inc. entered into a First Amendment to its Sublease Agreement with CRISPR Therapeutics, Inc. on June 29, 2026, according to an 8-K filed with the SEC. The amendment modifies a sublease agreement dated August 29, 2025, covering approximately 8,774 rentable square feet in the building at 105 West First Street, Boston, Massachusetts.1
Under the new terms, the sublandlord and Avalyn, as subtenant, agreed to expand the leased premises from approximately 8,774 rentable square feet to approximately 13,708 rentable square feet, effective June 29, 2026.1
The filing states that Avalyn's future minimum lease payments will increase by approximately $924,000 over the remaining lease term as a result of the amendment.1
All other terms of the original sublease agreement remain in full force and effect except as modified by this amendment.1
The complete text of the amendment was filed as Exhibit 10.1 to the report. The 8-K was signed by Lyn Baranowski, Chief Executive Officer of Avalyn Pharma, and dated July 1, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.